Preclinical studies with galanthamine

Drugs of Today

Volumn 33, Issue 4, 1997, Pages 259-264

  Mucke, Hermann A M ^a  

^a Waldheim Pharmazeutika GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE; HYDROCORTISONE; NEOSTIGMINE; SCOPOLAMINE;

ALZHEIMER DISEASE; AMNESIA; ANESTHESIOLOGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICHOLINERGIC EFFECT; BRADYCARDIA; BRAIN HEMORRHAGE; CLINICAL TRIAL; COGNITION; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; EOSINOPHILIA; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LD 50; MOUSE; MUSCULAR DYSTROPHY; MUTAGENICITY; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; REVIEW; TERATOGENICITY;

EID: 0030977647     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1997.33.4.425051     Document Type: Review

References (52)

1. Kobayashi, S., Shingu, T., Uyeo, S. The structure of galanthamine and lycoramine. Chem Ind 1956, 147-8.
2. Fales, H.M., Giuffrida, L.D., Wildman, W.C. Alkaloids of the Amaryllidaceae. VIII. The structures of narcissamine, leucorine, pseudoleucorine and methylpseudoleucorine. Am Chem Soc 1956, 78: 4145.
3. Boissier, J.R., Combes, G., Pagny, J. La galanthamine, puissant cholinergique naturel. I. Sources, structure chimique, extraction, toxicité. Action sur les fibres lisses. Ann Pharm Franc 1960, 18: 888-900.
4. Barton, D.H.R., Kirby, G.W. The synthesis of galanthamine. Proc Chem Soc 1960, 392-3.
5. Akhnazarova, S.L., Tolstykh, L.P., Rusakova, S.V. et al. Modeling and optimization of extraction of galanthamine from plant raw material. Fzv Uyssh Uchebn Zaved Khim Khim Tekhnol 1987, 30(5): 93-5.
6. Verfahren zur Herstellung von Derivaten des 4a,5,9,10,11,12 - hexahydro - 6H - benzofuro-(3a,3,2-ef)-benzazepins. AU 401058B.
7. Blagoeva, P., Balanski, R., Mircheva, T., Paskov, S. Nivalin genotoxicity. Med Biol Inf 1986, 4: 25-8.
8. Paskov, S. Nivalin. Pharmacological characteristics. Med Fitzkult (Sofia) 1959, 3: 272.
9. Institute for Drug Research, Budapest. Acute oral toxicity study with natural and synthetic galanthamine in rats. Protocol No. 9641, sponsored by Waldheim Pharmazeutika, 1996.
10. Institute for Drug Research, Budapest. 14-Day repeated dose comparative oral toxicity study with galanthamine in rats. Protocol 9625, sponsored by Waldheim Pharmazeutika, 1996.
11. Mashkovskiy, M.D., Kruglikova, L. Farmikol Toxikol 1951, 14: 27-30.
12. Irwin, H.L., Smith, H.J. Cholinesterase inhibition by galanthamine and lycoramine. Biochem Pharmacol 1960, 3: 147-8.
13. Taschev, T., Klimov, N. Uber die zentrale Wirkung des Nivalins. Folia Med 1961, 3(2): 65-70.
14. Uzunov, H., Georgiev, I., Acev, E. Attivitá bielletrica cerebrale e nivalinoterapia. Cult Med 1961, 25: 423-8.
15. Nesterenko, L.N. Influence exerted by galanthamine on the acetylcholine esterase activity in various regions of the brain. Farmakol Toxikol 1964, 28: 413-4.
16. Paskov, D.S., Dobrev, H., Nikoforov, N. Antagonistic action of Nivaline and morphine upon the repiratory center. Drugs and respiration. In: Proceedings of the 2nd International Pharmacological Meeting (Prague, 20-23 August, 1963). Pergamon Press: New York 1964, 113.
17. Ireson, J.D. A comparison of the antinociceptive action of cholinomimetics and morphine-like drugs. Br J Pharmacol 1970, 40: 92-101.
18. Pedigo, N.W., Dewey, W.L Acetylcholine-induced antinociception: Comparisons to opiate analgesia. In: Cholinergic Mechanisms. Pepeu, G., Landinsky, H. (Eds.). Plenum Press: New York 1981, 795-804.
19. Cozanitis, D.A., Friedmann, T., Fuerst, S. Study of the analgesic effects of galanthamine, a cholinesterase inhibitor. Arch Int Pharmacodyn 1983, 266: 229-38.
20. Tonkopii, V.D., Prozorovskii, V.B. Galanthamine interaction with mouse brain acetylcholinesterase in in vivo experiments. Biull Eksp Biol Med 1976, 82: 823-5.
21. Bickel, U., Thomsen, T., Fischer, J.P., Weber, W., Kewitz, H. Galanthamine: Pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 1991, 30(5): 447-54.
22. Thomsen, T., Kaden, B., Fischer, J.P. et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991, 29: 487-92.
23. Pazzagli, A., Pepeu, G. Amnesic properties of scopolamine and brain acetylcholine in the rat. Int J Neuropharmacol 1965, 4(5): 291-9.
24. Ilyutchenok, R.Y., Yeliseyeva, A.G. Cholinergic mechanisms of memory: Analysis of the amnesic effect of anticholinergic drugs. Int J Psychobiol 1972, 2(3): 177-92.
25. Chaplygina, S.R., Ilyutchenok, R.Y. Action of cholinergic substances in experimental amnesia. Zh Vyssh Nerv Deiat Im Pav 1976, 26(5): 1091-3.
26. Sweeney, J.E., Höhmann, C.F., Moran, T.H., Coyle, J.T. A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav 1988, 31(1): 141-7.
27. Sweeney, J.E., Bachman, E.S., Coyle, J.T. Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacology 1990, 102(2): 191-200.
28. Mashkovskii, M.D. Effects of galanthamine on the acetylcholine sensitivity of skeletal musculatura. Farmakol Toxikol 1955, 18(4): 21-7.
29. Stojanov, E.A. Galanthaminum hydrobromicum "Nivalin", ein neues Antidot der nichtdepolarisierenden Muskelrelaxantien. Der Anaesthesist 1963, 13(7): 217-20.
30. Pernov, K., Samardjiev, A., Nikolov, V. II trattamento delle distrofie muscolaro con dosi elevati di Nivalina. Cult Med 1961, 21: 1-16.
31. Kilimov, N. La cura die postumi paralitici da emorragia cerebrale mediante Nivalina. Cult Med 1961, 23: 313-22.
32. Revelli, U., Grasso, E. La terapia nivalinica (Galanthus nivalis) nella malattia poliomielitica. Minerva Med 1962, 53(24): 881-4.
33. Baraka, A., Cozanitis, D.A. Galanthamine versus neostigmine for reversal of nondepolarizing neuromuscular block in man. Curr Res 1973, 52(5): 832-6.
34. Cozanitis, D.A., Toivakka, E. A comparative study of galanthamine hydrobromide and atropine/neostigmine in conscious volunteers. Anaesthesist 1971, 20(11): 416-21.
35. Cozanitis, D.A., Toivakka, E., Dessypris, A. Electroencephalographic and blood chemistry responses to galanthamine hydrobromide in epileptic volunteers. Anaesthesist 1973, 22: 31-3.
36. Cozanitis, D.A. Galanthamine hydrobromide versus neostigmine: A plasma cortisol study in man. Anaesthesia 1974, 29: 163-8.
37. Cozanitis, D.A., Nuuttila, K., Karhunen, P., Baraka, A. Changes in cardiac rhythm with galanthamine hydrobromide. Anaesthesist 1973, 22: 457-9.
38. Davis, B.M., Davis, K.L. Cholinergic mechanisms and pituitary hormone secretion. Biol Psychiatry 1980, 15: 303-10.
39. Riemann, D., Gann, H., Dressing, H., Müller, W.E., Aldenhoff, J.B. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatry Res 1994, 51: 253-67.
40. Moormann, A. Verwendung von Galanthamin zur Behandlung der Nikotinabhangigkeit. DE 4301782C1.
41. Opitz, K. Verwendung von Galanthamin zur Behandlung des Alkoholismus. DE 4010079C2.
42. Snorrason, E. Choline esterase inhibitor for avoidance of benzodiazepine side effects. US 5312817.
43. Katz, R. Method of treating physiologic male erectile impotence. US 5177070.
44. Sorrason, E. Treatment of fatigue syndrome with cholinesterase inhibitors. WO 9220327.
45. Hille, D., Deurer, L. Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil. DE 4301783C1.
46. Shire Pharmaceuticals Group plc 1995 Corporate Review.
47. Mucke, H.A.M. Principles of therapeutics of galanthamine. Drugs Today 1997, 33(4): in press.
48. Baraka, A., Harik, S. Reversal of central anticholinergic syndrome by galanthamine. J Am Med Assoc 1977, 238(21): 2293-4.
49. Rainer, M. Clinical studies with galanthamine. Drugs Today 1997, 33(4): in press.
50. Fulton, B., Benfield, P. Galanthamine. Drugs Aging 1996, 9(1): 60-5.
51. Rainer, M. Galanthamine in Alzheimer's disease: A new alternative to tacrine? CNS Drugs 1997, 7(2): 89-97.
52. MacPherson, S. Galanthamine, the new treatment of choice in Alzheimer's disease? Inpharma 1995,1002: 3-5.